Trial Profile

A first in human study of MaaT 034

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MaaT 034 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

28 Mar 2024 According to a MaaT Pharma media release, the company expects the first clinical batches of MaaT034 to be produced in 2024.
01 Oct 2023 New trial record
25 Sep 2023 According to a MaaT Pharma media release, the company plans to initiate this study in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com